TY - JOUR
T1 - Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C
T2 - Association with treatment response
AU - Haas, Stephan L.
AU - Wei, Christel
AU - Bugert, Peter
AU - Gundt, Jutta
AU - Witt, Heiko
AU - Singer, Manfred V.
AU - Berg, Thomas
AU - Böcker, Ulrich
N1 - Funding Information:
This work was supported by the German Competence Network for Viral Hepatitis (Hep-Net), funded by the German Ministry of Education and Research (BMBF, Grant No. 01 KI 0437, Project No. 10.1.3 Core Project No. 10.1 Genetic host factors in viral hepatitis and Genetic Epidemiology Group in viral hepatitis) and by the EU-Vigilanz network of excellence combating viral resistance (VIRGIL, Projekt No. LSHM-CT-2004-503359) and by the BMBF Project: Host and viral determinants for susceptibility and resistance to hepatitis C virus infection.
PY - 2009/9
Y1 - 2009/9
N2 - Background: Recently, two functional IL18 promoter variants, -607C>A (rs1946518) and -137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response. Methods: Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%. Results: Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p=0.0416 and p=0.0274, respectively). In viral genotype 1, the -607A allele was positively associated with treatment response (p=0.0190; OR 1.537; 95% CI, 1.072-2.205) and the -137G allele with a higher rate of nonresponse (p=0.0302; OR 1.524; 95% CI, 1.040-2.233). Conclusions: The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.
AB - Background: Recently, two functional IL18 promoter variants, -607C>A (rs1946518) and -137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response. Methods: Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%. Results: Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p=0.0416 and p=0.0274, respectively). In viral genotype 1, the -607A allele was positively associated with treatment response (p=0.0190; OR 1.537; 95% CI, 1.072-2.205) and the -137G allele with a higher rate of nonresponse (p=0.0302; OR 1.524; 95% CI, 1.040-2.233). Conclusions: The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.
KW - Antiviral therapy
KW - Genetic alterations
KW - Hepatitis C
KW - Interleukin 18
KW - Treatment outcome
UR - http://www.scopus.com/inward/record.url?scp=69249220140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69249220140&partnerID=8YFLogxK
U2 - 10.1007/s10875-009-9302-z
DO - 10.1007/s10875-009-9302-z
M3 - Article
C2 - 19455410
AN - SCOPUS:69249220140
SN - 0271-9142
VL - 29
SP - 620
EP - 628
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 5
ER -
